ESMO GI 2026 | TRIPP-FFX: targeted intratumoral P-32 microparticles with FOLFIRINOX in uLAPC

Michele Milella, MD, University of Verona, Verona, Italy, discuss the trial design and results from the randomized non-comparative TRIPP-FFX study (NCT05466799) evaluating the feasibility and tolerability of induction FOLFIRINOX chemotherapy with targeted intratumoral placement of phosphorus-32 (P-32) microparticles in unresectable locally advanced pancreatic cancer (uLAPC). Patients were also randomized to FOLFIRINOX chemotherapy alone to provide a calibration but not comparative arm. The local disease control rate (DCR) at 16 weeks was 82% in the intent-to-treat population from the combination arm and 56% in the per-protocol population. No new toxicity signals were observed and 6 adverse events were reported that were related to implantation. In the per-protocol population, the progression-free survival, overall survival and time to local disease progression were numerically higher in the combination arm than the FOLFIRINOX alone arm, however as this was a non-comparative study, the significance of this was not assessed. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.